CBX Chromodomain Inhibition Enhances Chemotherapy Response in Glioblastoma Multiforme

Glioblastoma multiforme (GBM) lacks effective therapeutic options leaving patients with a survival time of approximately one year. Recently, the alteration of chromatin modulators has been implicated in the pathogenesis and chemoresistance of numerous cancers; in particular, the Polycomb Group Prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Connelly, Katelyn E., Martin, Emily C., Dykhuizen, Emily C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: YJBM 2016
Materias:
Original Contribution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168823/
https://www.ncbi.nlm.nih.gov/pubmed/28018136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168823/
https://www.ncbi.nlm.nih.gov/pubmed/28018136

Ejemplares similares